MedPath

Medical University of South Carolina

Medical University of South Carolina logo
🇺🇸United States
Ownership
Private
Established
1955-01-01
Employees
10K
Market Cap
-
Website
https://www.muschealth.com

Clinical Trials

812

Active:25
Completed:535

Trial Phases

6 Phases

Early Phase 1:36
Phase 1:77
Phase 2:130
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (725 trials with phase data)• Click on a phase to view related trials

Not Applicable
416 (57.4%)
Phase 2
130 (17.9%)
Phase 1
77 (10.6%)
Phase 4
45 (6.2%)
Early Phase 1
36 (5.0%)
Phase 3
21 (2.9%)

Remimazolam vs Propofol in Laser Burn Cases

Not Applicable
Not yet recruiting
Conditions
Burn Scar
Hypertrophic Scarring
Procedural Sedation
Interventions
First Posted Date
2025-10-09
Last Posted Date
2025-10-09
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
136
Registration Number
NCT07213544
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

Thermodynamic Exposure and Sleep in Military Cadets

Not Applicable
Not yet recruiting
Conditions
Cold-water Immersion
High Heat Sauna
Combination of Cold-water Immersion and High Heat Sauna
First Posted Date
2025-10-01
Last Posted Date
2025-10-01
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
45
Registration Number
NCT07201935
Locations
🇺🇸

The Citadel Military College, Charleston, South Carolina, United States

Motoneuron Recruitment and Motor Evoked Potential Up-Conditioning (MEP) in Spinal Cord Injury (SCI)

Not Applicable
Not yet recruiting
Conditions
Spinal Cord Injuries and Disorders (SCI/D)
Spinal Cord Injury
First Posted Date
2025-09-18
Last Posted Date
2025-09-18
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
15
Registration Number
NCT07179822
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Protocol for Patients Living With Metastatic Lung Cancer

Not Applicable
Not yet recruiting
Conditions
Survivorship
First Posted Date
2025-09-17
Last Posted Date
2025-09-22
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
80
Registration Number
NCT07177846

Peripheral Nerve Stimulation With the SPRINT® System in Chronic PSIJC Pain

Not Applicable
Not yet recruiting
Conditions
Lower Back Pain
First Posted Date
2025-09-11
Last Posted Date
2025-09-11
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
10
Registration Number
NCT07166952
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 163
  • Next

News

MUSC Researchers Engineer CHAR-Tregs to Target Organ Rejection with Precision Immunosuppression

Medical University of South Carolina researchers have developed genetically engineered regulatory T-cells equipped with chimeric anti-HLA antibody receptors (CHARs) that can precisely target and neutralize antibody-producing B-cells responsible for organ rejection.

LiveKidney Initiates Phase I/IIa Trial of Novel Cell Therapy LK-SC001 for Lupus Nephritis

• LiveKidney has enrolled the first patient in a Phase I/IIa clinical trial evaluating LK-SC001, a subcutaneous UC-MSC therapy, for lupus nephritis and systemic lupus erythematosus at the Medical University of South Carolina. • The investigational therapy utilizes umbilical cord-derived mesenchymal stromal cells in a proprietary hydrogel formulation designed to release immunomodulatory compounds that may improve kidney function and reduce inflammation. • Current lupus treatments are effective in only 40% of patients, highlighting the significant unmet need that LK-SC001 aims to address through its novel mechanism targeting the complex immunological nature of the disease.

Home Administration of Long-Acting HIV Injectable Therapy Proves Safe and Effective as Clinic Treatment

A study by the Medical University of South Carolina demonstrates that home administration of long-acting injectable antiretroviral therapy (ART) for HIV patients is as safe and effective as clinic-based administration.

Enhanced Navigation Program Significantly Improves Timing of Post-Surgery Radiation in Head and Neck Cancer

A novel patient navigation intervention (NDURE) doubled the rate of timely post-operative radiation therapy initiation in head and neck cancer patients, showing a 35% improvement over usual care.

Dental Flossing Associated with 22% Lower Stroke Risk and Reduced AFib in 25-Year Study

A landmark 25-year study reveals regular dental flossing is linked to a 22% lower risk of ischemic stroke and 44% reduction in cardioembolic stroke risk, independent of other oral hygiene practices.

MUSC Launches Clinical Trial for Revolutionary Wire-Free Cochlear Implant System

The Medical University of South Carolina (MUSC) has been selected as one of seven national sites to test an innovative fully implantable cochlear implant system without external components.

Study Calls for Optimization of High-Cost IVIG Therapy in BK Nephropathy Treatment

Research from the Medical University of South Carolina indicates that single-dose IVIG therapy (2g/kg) may be sufficient for clearing BK viral load in nephropathy patients, potentially reducing overall treatment costs.

Global Experts Share Strategies to Enhance Lung Cancer Screening Access and Early Detection

Healthcare experts at the 2024 World Conference on Lung Cancer presented innovative approaches to improve lung cancer screening uptake, emphasizing the need for tailored recruitment strategies and digital solutions.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.